Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.

Rubin, David T; Cohen, Russell D; Sandborn, William J; Lichtenstein, Gary R; Axler, Jeffrey; Riddell, Robert H; Zhu, Cindy; Barrett, Andrew C; Bortey, Enoch; Forbes, William P

Rubin, David T; Cohen, Russell D; Sandborn, William J; Lichtenstein, Gary R; Axler, Jeffrey; Riddell, Robert H; Zhu, Cindy; Barrett, Andrew C; Bortey, Enoch; Forbes, William P.

Afiliação

Rubin DT; Inflammatory Bowel Disease Center, University of Chicago Medicine, USA.
Cohen RD; Inflammatory Bowel Disease Center, University of Chicago Medicine, USA.
Sandborn WJ; Division of Gastroenterology, University of California [UC] San Diego and UC San Diego Health System, USA.
Lichtenstein GR; Division of Gastroenterology, Perelman School of Medicine of the University of Pennsylvania, USA.
Axler J; Toronto Digestive Disease Associates, Canada.
Riddell RH; Department of Pathology and Laboratory Medicine, Mt Sinai Hospital, Canada.
Zhu C; Salix Pharmaceuticals, USA.
Barrett AC; Salix Pharmaceuticals, USA.
Bortey E; Salix Pharmaceuticals, USA.
Forbes WP; Salix Pharmaceuticals, USA.

J Crohns Colitis ; 11(12): 1510, 2017 12 04.

Article em En | MEDLINE | ID: mdl-28453665

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: J Crohns Colitis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google